Labetuzumab ELISA Kit (DY546028)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DY546028
Type d'échantillon	Plasma, Serum
Sensibilité	53.67 ng/mL
Plage	156.25 - 10, 000 ng/mL
Numéro d'accès	P06731
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Spécifications	Labetuzumab
Noms alternatifs	hMN14, IMMU-130, hMN-14-SN-38, hMN-14-SN-38 ADC, hMN14-CL-SN-38, Labetuzumab Govitecan, 219649-07-7
Contexte	Cell adhesion molecule CEACAM5 (Labetuzumab) is a ~76 kDa protein. Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells. 1. Taheri, M. et al. (2000) The Journal of biological chemistry 275, 26935-43. PMID: 10864933 2. Ordoñez, C. et al. (2000) Cancer research 60, 3419-24. PMID: 10910050 3. Oikawa, S. et al. (1989) Biochemical and biophysical research communications 164, 39-45. PMID: 2803308
Reférences	1. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. [DY546028] 2. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47. [DY546028] 3. Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20. [DY546028]
Note	For Research Use Only.